Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review

Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases

“…The updated systematic review by Nam et al (2014) used to inform the 2013 update of the European League against Rheumatism (EULAR) guidelines for the management of RA concluded that although there was some additional evidence for the use of biologic monotherapy, a biologic in combination with MTX is more efficacious than the same biologic agent alone. In addition, there is also accumulating evidence from trial and registry data that the coprescription of MTX with biologics improves drug survival and persistence with the therapy (Blum et al, 2011;Soliman et al, 2011;Iannone et al, 2012), so combination therapy is now recommended in most treatment guidelines for the use of TNF inhibitors in RA.…”

Persistence with Biologic Agents for the Treatment of Rheumatoid Arthritis in Japan

“…A systematic review of 52 studies found persistence rates between 32.0% and 90.9% after 1 year. 6 These rather large variations indicate that institutional and probably cultural factors play a role in explaining the magnitude of persistence rates. Results are therefore contingent on the respective health care delivery system and it is difficult to compare the findings between countries.…”

New Recommendations for the Management of Rheumatoid Arthritis (Eular, 2013): The Role of Methotrexate

“…МТ повышает эффективность ингибиторов ФНОα (ИНФ и АДА) за счет разных механизмов, в том числе в связи с подавлением иммуногенности этих моноклональных ан-тител [46,102]. Наряду с материалами РПКИ, данные от-крытых наблюдательных исследований [103,104] и нацио-нальных регистров [105][106][107][108][109][110][111], а также их метаанализ [112] свидетельствуют о более высокой эффективности комби-нированной терапии МТ и ингибиторами ФНОα по срав-нению с монотерапией этими препаратами.…”